Sunshine Biopharma’s Revenue Soars 54% in Q1 Sunshine Biopharma (SBFM) has released an update. Sunshine Biopharma has reported a significant 54% increase in revenue to $7.54 million in the fir…
SBFM Stock Earnings: Sunshine Biopharma Beats EPS, Beats Revenue for Q1 2024 Sunshine Biopharma (NASDAQ: SBFM ) just reported results for the first quarter of 2024. Sunshine Biopharma reported earnings per share of -$2.00. This was above the analyst estimate for EPS of -$8.00. The company reported revenue of $7.54 million. This was 7.73% better than the analyst estimate for revenue of $7.00 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora Pharma, has received approval for its first Biosimilar product. Nora Pharma has received approval from Health Canada for the commercialization of NIOPEG® (a pegylated form of filgrastim) in Canada.
How Is The Market Feeling About Sunshine Biopharma? Sunshine Biopharma''s (NYSE: SBFM ) short percent of float has fallen 27.45% since its last report. The company recently reported that it has 706 thousand shares sold short , which is 0.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Reverse Stock Split NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medicines …
Sunshine Biopharma Announces Reverse Stock Split NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, announced today a one for one hundred reverse split of its common stock, effective at market open on April 17, 2024. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing.
SBFM Stock Earnings: Sunshine Biopharma Misses EPS, Beats Revenue for Q4 2023 Sunshine Biopharma (NASDAQ: SBFM ) just reported results for the fourth quarter of 2023. Sunshine Biopharma reported earnings per share of -6 cents. This was below the analyst estimate for EPS of -3 cents. The company reported revenue of $7.68 million. This was 25.90% better than the analyst estimate for revenue of $6.10 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.